Fundraising Fox
/Companies
Sign in

Archon

Seattle, US · 27 employees on LinkedIn · 3 known investors

Find your way into Archon

4 people in our graph can introduce you to the Archon team.

Sign up to see every warm intro you have to Archon

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Archon team. We find them
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Archon Biosciences develops a computational protein design platform leveraging AI and deep learning for therapeutic and vaccine applications. The company was founded in 2023 by James Lazarovits and George Ueda, Ph.D., building on research in AI-driven protein engineering and nanomaterial delivery.

AI & Machine LearningBiotechDeep Tech

Founders & leadership

GUGeorge Ueda, Ph.D.
George Ueda, Ph.D.Chief Technology Officer, Co-Founder
JL
James Lazarovits, Ph.D.Chief Executive Officer, Co-Founder
JLJames Lazarovits
James LazarovitsCo-Founder and CEOBiomedical engineer with background in software, hardware, and robotics startups and investment, now co-founder of Archon Biosciences, which develops AI-driven protein design technology for therapeutic and vaccine applications.
GUGeorge Ueda
George UedaCo-Founder and CTO
DB
David BakerFounder
LS
Lance StewartFounder

Investors · 3

Madrona Venture Grouplisted by Madrona Venture GroupSeattle · $2M – $10M

How we know: Madrona Venture Group's portfolio page · a partner's Signal profile · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Y CombinatorreportedSan Francisco · $500K

How we know: funding news · Not right? Tell us

Related companies · 3

CreyonCreyon develops aptamer-delivered oligonucleotide therapeutics for targeted cell-specific delivery, including small interfering RNA and antisense oligonucleotides. The company's platform addresses limitations in tissue penetration and immunogenicity for central nervous system and other tissue-targeted applications.
Regeneron NASDAQ: REGN www.regeneron.comRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
Orca BioOrca Bio develops allogeneic T-cell immunotherapies for high-risk blood cancers including acute myeloid leukemia, acute lymphocytic leukemia, and myelodysplastic syndrome. The company is advancing precision cell therapy treatments for patients with blood cancers and autoimmune diseases.

Companies working in the same space as Archon.

In the news

Archon Biosciences Emerges from Stealth to Advance a New Class of Biologic Invented in Nobel Prize-Winning Computational Protein Design Lab — Archon Bioarchon.bio · Oct 2024Archon Biosciences Raises $20M in Seed Fundingfinsmes.com · Oct 2024

Frequently asked questions

What does Archon do?
Archon Biosciences develops a computational protein design platform leveraging AI and deep learning for therapeutic and vaccine applications. The company was founded in 2023 by James Lazarovits and George Ueda, Ph.D., building on research in AI-driven protein engineering and nanomaterial delivery.
Who founded Archon?
Archon was founded by George Ueda, Ph.D., James Lazarovits, Ph.D., James Lazarovits, George Ueda.
Who are Archon's investors?
Archon's investors include Cornucopian Capital Management, Madrona Venture Group, Y Combinator.
Where is Archon headquartered?
Archon is headquartered in Seattle, US.